Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal



Hazard - P - B - T - Risk See below

Risk. See below.

Assessment report

Assessment report for Emgality (galcanezumab) 20 September 2018 EMA/708631/2018.

"The active substance galcanezumab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, galcanezumab is not expected to pose a risk to the environment."

Fass environmental information

Environmental information for galcanezumab is not available on Fass.se (2020-10-06). It is voluntary for manufacturers to publish environmental impact information on Fass.se.

Author: Health and Medical Care Administration, Region Stockholm